Trials that use: Risk difference
New to this method? Read the tutorial →
4,772 results
- A Study of LY2541546 in Healthy Postmenopausal Women: Complete Statistical AnalysisIndependent statistical analysis of A Study of LY2541546 in Healthy Postmenopausal Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01742078).
- A Study of LY2624803 in Japanese Participants With Transient Insomnia: Complete Statistical AnalysisIndependent statistical analysis of A Study of LY2624803 in Japanese Participants With Transient Insomnia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01784614).
- A Study of LY2928057 in Hemodialysis Participants: Complete Statistical AnalysisIndependent statistical analysis of A Study of LY2928057 in Hemodialysis Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01991483).
- A Study of LY2940680 in Japanese Participants With Advanced Cancers: Complete Statistical AnalysisIndependent statistical analysis of A Study of LY2940680 in Japanese Participants With Advanced Cancers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01919398).
- A Study of LY2944876 in Healthy Japanese and Non-Japanese Participants: Complete Statistical AnalysisIndependent statistical analysis of A Study of LY2944876 in Healthy Japanese and Non-Japanese Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02188303).
- A Study of LY3006072 in Healthy Participants: Complete Statistical AnalysisIndependent statistical analysis of A Study of LY3006072 in Healthy Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01640249).
- A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- A Study of LY3039478 in Participants With Advanced Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study of LY3039478 in Participants With Advanced Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01695005).
- A Study of LY3041658 in Adults With Hidradenitis Suppurativa: Complete Statistical AnalysisIndependent statistical analysis of A Study of LY3041658 in Adults With Hidradenitis Suppurativa: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04493502).
- A Study of LY3050258 in Healthy Participants: Complete Statistical AnalysisIndependent statistical analysis of A Study of LY3050258 in Healthy Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02121834).
- A Study of LY3053102 in Healthy Participants: Complete Statistical AnalysisIndependent statistical analysis of A Study of LY3053102 in Healthy Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01736241).
- A Study of LY3113593 in Participants With Chronic Kidney Disease: Complete Statistical AnalysisIndependent statistical analysis of A Study of LY3113593 in Participants With Chronic Kidney Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02604160).
- A Study of LY3185643 and rGlucagon in Healthy Participants: Complete Statistical AnalysisIndependent statistical analysis of A Study of LY3185643 and rGlucagon in Healthy Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02951780).
- A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight: Complete Statistical AnalysisIndependent statistical analysis of A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- A Study of LY3463251 in Healthy Participants: Complete Statistical AnalysisIndependent statistical analysis of A Study of LY3463251 in Healthy Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03764774).
- A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities: Complete Statistical AnalysisIndependent statistical analysis of A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus: Complete Statistical AnalysisIndependent statistical analysis of A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- A Study of LY3526318 in Healthy Participants: Complete Statistical AnalysisIndependent statistical analysis of A Study of LY3526318 in Healthy Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03977974).
- A Study of LY3832479 (LY-CoV016) in Healthy Participants 1: Complete Statistical AnalysisIndependent statistical analysis of A Study of LY3832479 (LY-CoV016) in Healthy Participants 1: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04611789).
- A Study of LY900014 Formulations in Healthy Participants: Complete Statistical AnalysisIndependent statistical analysis of A Study of LY900014 Formulations in Healthy Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02317575).
- A Study of LY900014 in Participants With Type 2 Diabetes Mellitus: Complete Statistical AnalysisIndependent statistical analysis of A Study of LY900014 in Participants With Type 2 Diabetes Mellitus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin’s Lymphoma (NHL): Complete Statistical AnalysisIndependent statistical analysis of A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Complete Statistical AnalysisIndependent statistical analysis of A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma: primary endpoint results, effect estimate with confidence…
- A Study of Magnetic Resonance Imaging (MRI) With Gadavist in Children: Complete Statistical AnalysisIndependent statistical analysis of A Study of Magnetic Resonance Imaging (MRI) With Gadavist in Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- A Study of Management of Tarceva – Induced Rash in Patients With Non-Small Cell Lung Cancer.: Complete Statistical AnalysisIndependent statistical analysis of A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis: Complete Statistical AnalysisIndependent statistical analysis of A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML: Complete Statistical AnalysisIndependent statistical analysis of A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.: Complete Statistical AnalysisIndependent statistical analysis of A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- A Study of Mirikizumab in Participants With Plaque Psoriasis: Complete Statistical AnalysisIndependent statistical analysis of A Study of Mirikizumab in Participants With Plaque Psoriasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03718884).
- A Study of MK-2060 in Participants With Chronic and/or End-Stage Kidney Disease (MK-2060-011): Complete Statistical AnalysisIndependent statistical analysis of A Study of MK-2060 in Participants With Chronic and/or End-Stage Kidney Disease (MK-2060-011): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- A Study of Mobile Medical Supportive Care Program for Family Caregivers With Dementia Combined With Diabetes: Complete Statistical AnalysisIndependent statistical analysis of A Study of Mobile Medical Supportive Care Program for Family Caregivers With Dementia Combined With Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- A Study of MORAb-202 Versus Investigator’s Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer: primary endpoint results, effect estimate…
- A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression: Complete Statistical AnalysisIndependent statistical analysis of A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults: Complete Statistical AnalysisIndependent statistical analysis of A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05415462).
- A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults: Complete Statistical AnalysisIndependent statistical analysis of A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer: primary endpoint results, effect estimate with confidence…
- A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC): Complete Statistical AnalysisIndependent statistical analysis of A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size…
- A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL): Complete Statistical AnalysisIndependent statistical analysis of A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL): Complete Statistical AnalysisIndependent statistical analysis of A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax…
- A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis: Complete Statistical AnalysisIndependent statistical analysis of A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- A Study of ONO-7475 in Patients With Acute Leukemias: Complete Statistical AnalysisIndependent statistical analysis of A Study of ONO-7475 in Patients With Acute Leukemias: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03176277).
- A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II): Complete Statistical AnalysisIndependent statistical analysis of A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II): primary endpoint results, effect estimate with confidence…
- A Study of Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Participants Who Have Experienced CINV(Chemotherapy-Induced Nausea and Vomiting) During the Previous Cycle of Low Emetogenic Chemotherapy (LEC): Complete Statistical AnalysisIndependent statistical analysis of A Study of Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Participants Who Have Experienced CINV(Chemotherapy-Induced Nausea and Vomiting) During the Previous Cycle of Low…
- A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin’s Lymphoma Grades 1, 2 or 3a: Complete Statistical AnalysisIndependent statistical analysis of A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a:…
- A Study of Patients Who Received Inotuzumab Ozogamicin for B-cell ALL (Acute Lymphoblastic Leukemia) That Occurred Again After the Last Treatment: Complete Statistical AnalysisIndependent statistical analysis of A Study of Patients Who Received Inotuzumab Ozogamicin for B-cell ALL (Acute Lymphoblastic Leukemia) That Occurred Again After the Last Treatment: primary endpoint results, effect estimate with confidence…